Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

AnHeart Closes $61 Million Round for Precision Oncology Therapies

publication date: Dec 14, 2021

Hangzhou AnHeart Therapeutics closed a $61 million Series B funding to develop precision oncology therapies. The financing was led by new investor Octagon Capital, with participation from Suzhou's Innovent Biologics. In June, Innovent struck a deal with AnHeart to co-develop and commercialize AnHeart’s lead drug candidate, taletrectinib, in greater China. Taletrectinib is a next-generation TKI that targets ROS1 and NTR to treat solid tumors. Cenova, Laurion Capital, and Sage Partners also participated in the B round. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital